Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.59
FLDM's Cash to Debt is ranked higher than
58% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. FLDM: 0.59 )
FLDM' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 0.59

Equity to Asset 0.37
FLDM's Equity to Asset is ranked higher than
55% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. FLDM: 0.37 )
FLDM' s 10-Year Equity to Asset Range
Min: -7.63   Max: 0.89
Current: 0.37

-7.63
0.89
F-Score: 2
Z-Score: 1.73
M-Score: 1.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -44.51
FLDM's Operating margin (%) is ranked higher than
60% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.24 vs. FLDM: -44.51 )
FLDM' s 10-Year Operating margin (%) Range
Min: -338.59   Max: -26.2
Current: -44.51

-338.59
-26.2
Net-margin (%) -45.36
FLDM's Net-margin (%) is ranked higher than
59% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. FLDM: -45.36 )
FLDM' s 10-Year Net-margin (%) Range
Min: -368.13   Max: -23.22
Current: -45.36

-368.13
-23.22
ROE (%) -36.15
FLDM's ROE (%) is ranked higher than
58% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. FLDM: -36.15 )
FLDM' s 10-Year ROE (%) Range
Min: -42.81   Max: -16.77
Current: -36.15

-42.81
-16.77
ROA (%) -14.86
FLDM's ROA (%) is ranked higher than
63% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. FLDM: -14.86 )
FLDM' s 10-Year ROA (%) Range
Min: -67.71   Max: -14.33
Current: -14.86

-67.71
-14.33
ROC (Joel Greenblatt) (%) -277.54
FLDM's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. FLDM: -277.54 )
FLDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -839.76   Max: -156.13
Current: -277.54

-839.76
-156.13
Revenue Growth (3Y)(%) 20.40
FLDM's Revenue Growth (3Y)(%) is ranked higher than
95% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. FLDM: 20.40 )
FLDM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 20.4
Current: 20.4

0
20.4
EBITDA Growth (3Y)(%) 11.60
FLDM's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. FLDM: 11.60 )
FLDM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 11.6
Current: 11.6

0
11.6
EPS Growth (3Y)(%) 1.60
FLDM's EPS Growth (3Y)(%) is ranked higher than
75% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. FLDM: 1.60 )
FLDM' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 1.6
Current: 1.6

0
1.6
» FLDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

FLDM Guru Trades in Q1 2014

RS Investment Management 309,100 sh (+10.36%)
PRIMECAP Management 3,484,821 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2014

FLDM Guru Trades in Q2 2014

Jim Simons 49,500 sh (New)
RS Investment Management 524,648 sh (+69.73%)
PRIMECAP Management 3,651,332 sh (+4.78%)
» More
Q3 2014

FLDM Guru Trades in Q3 2014

RS Investment Management 536,748 sh (+2.31%)
PRIMECAP Management 3,689,632 sh (+1.05%)
Jim Simons Sold Out
» More
Q4 2014

FLDM Guru Trades in Q4 2014

RS Investment Management 793,478 sh (+47.83%)
PRIMECAP Management 3,726,832 sh (+1.01%)
» More
» Details

Insider Trades

Latest Guru Trades with FLDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.90
FLDM's P/B is ranked higher than
51% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. FLDM: 6.90 )
FLDM' s 10-Year P/B Range
Min: 3.4   Max: 12.53
Current: 6.9

3.4
12.53
P/S 8.80
FLDM's P/S is ranked lower than
59% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.51 vs. FLDM: 8.80 )
FLDM' s 10-Year P/S Range
Min: 0.94   Max: 16.73
Current: 8.8

0.94
16.73
EV-to-EBIT -22.73
FLDM's EV-to-EBIT is ranked higher than
68% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. FLDM: -22.73 )
FLDM' s 10-Year EV-to-EBIT Range
Min: -60   Max: -6.1
Current: -22.73

-60
-6.1
Current Ratio 5.31
FLDM's Current Ratio is ranked higher than
88% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. FLDM: 5.31 )
FLDM' s 10-Year Current Ratio Range
Min: 1.13   Max: 8.73
Current: 5.31

1.13
8.73
Quick Ratio 4.76
FLDM's Quick Ratio is ranked higher than
87% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. FLDM: 4.76 )
FLDM' s 10-Year Quick Ratio Range
Min: 0.86   Max: 8.11
Current: 4.76

0.86
8.11
Days Inventory 120.76
FLDM's Days Inventory is ranked higher than
72% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 141.40 vs. FLDM: 120.76 )
FLDM' s 10-Year Days Inventory Range
Min: 102.81   Max: 443.32
Current: 120.76

102.81
443.32
Days Sales Outstanding 70.16
FLDM's Days Sales Outstanding is ranked higher than
76% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 84.80 vs. FLDM: 70.16 )
FLDM' s 10-Year Days Sales Outstanding Range
Min: 54.11   Max: 124.82
Current: 70.16

54.11
124.82

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
FLDM's Price/Median PS Value is ranked higher than
65% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. FLDM: 1.20 )
FLDM' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.94
Current: 1.2

0.75
1.94
Earnings Yield (Greenblatt) -4.60
FLDM's Earnings Yield (Greenblatt) is ranked higher than
56% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. FLDM: -4.60 )
FLDM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.6   Max: 0
Current: -4.6

-4.6
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:FLB.Germany,
Fluidigm Corp is a Delaware Corporation formed in May, 1999. The Company develops, manufacture, and market microfluidic systems to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. These systems are designed to simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. The current markets for its products include life science research, clinical research, and Ag-Bio. The proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. The Company's primary area of development within life science research is genetic analysis, the study of genes and their functions. Genetic analysis techniques, such as SNP genotyping, genotyping by sequencing, and genotyping by real-time PCR analysis, have become increasingly useful in Ag-Bio applications, including wildlife population studies, agricultural quality control, and commercial genetic engineering and identification. It actively market four microfluidic systems, including 18 different commercial IFCs for nucleic acid analysis, as well as three families of assay chemistries. Its systems are based on one or more IFCs designed for particular applications and include specialized reagents, instrumentation, and software. The Company distributes its microfluidic systems through its direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. It has sold its C1 Single-Cell Auto Prep, BioMark, BioMark HD, EP1, and Access Array systems to the academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. The Company has sold approximately 920 systems to customers in over 35 countries. Its microfluidic systems and instrumentation for commercial sale, as well as for internal research and development purposes, are manufactured at its facilities in Singapore. The Company also manufactures IFCs for research and development and its assay chemistries at its headquarters in South San Francisco, California. It competes with companies such as Affymetrix, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Life Technologies Corporation (now part of Thermo Fisher Scientific), LGC Limited, Luminex Corporation, NanoString Technologies, Inc., PerkinElmer, Inc. (through its acquisition of Caliper Life Sciences, Inc.), RainDance Technologies, Inc., Roche Applied Science (a division of Roche Diagnostics Corporation), Sequenom, Inc., Thermo Fisher Scientific Inc., and WaferGen Bio-Systems, Inc.
» More Articles for FLDM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Fluidigm to Announce Q1 2015 Financial Results and Host Conference Call for Investors Apr 30 2015
Thermo Fisher Q1 Earnings Top, Revenues Lag Estimates - Analyst Blog Apr 22 2015
Inogen Gains despite Further Delay in Form 10-K Filing - Analyst Blog Apr 16 2015
Thoratec Hits 52-Week High on Favorable Developments - Analyst Blog Apr 16 2015
Masimo to Launch Patient SafetyNet System with Iris, MyView - Analyst Blog Apr 14 2015
DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog Apr 13 2015
AngioDynamics Lags Earnings on Lower Sales, View Tepid - Analyst Blog Apr 10 2015
FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Apr 08 2015
Luminex (LMNX) Launches NxTAG RPP for Respiratory Testing - Analyst Blog Apr 07 2015
Inogen Fails 10-K Deadline; Files Form 12b-25 for Extra Time - Analyst Blog Apr 01 2015
The Best and Worst Medalists of 2015's First Quarter Mar 30 2015
Inogen's Texas Facility Ready, Costs Likely to Scale Down - Analyst Blog Mar 26 2015
Abiomed Attains New 52-Week High on Impella 2.5 Approval - Analyst Blog Mar 25 2015
Abiomed's Impella 2.5 FDA-Approved for PCI Procedures - Analyst Blog Mar 24 2015
Cantel Medical Beats Q2 Earnings, Provides Positive Outlook - Analyst Blog Mar 13 2015
Inogen (INGN) Postpones Q4 Results; Reiterates 2015 View - Analyst Blog Mar 12 2015
FLUIDIGM CORP Financials Mar 05 2015
Symmetry Surgical Posts Loss in Q4, Revenues Decline Y/Y - Analyst Blog Mar 02 2015
10-K for Fluidigm Corp. Feb 28 2015
FLUIDIGM CORP Files SEC form 10-K, Annual Report Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK